Advertisement

Topics

Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer (pdf 284KB)

05:00 EST 9 Nov 2017 | Astellas Pharma Inc.

Original Article: Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer (pdf 284KB)

NEXT ARTICLE

More From BioPortfolio on "Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer (pdf 284KB)"

Advertisement
Quick Search
Advertisement
Advertisement